(33/172) of microcatheters. Fifty-three (86.9%) of the 61 patients who underwent embolization with the Apollo microcatheter had good functional outcomes (modified Rankin Scale score 0-2). No unintended microcatheter fractures or related morbidity was observed. One patient died of intraprocedural complications unrelated to microcatheter selection. In the univariate analysis, microcatheter tip detachment (p = 0.12), single embolized pedicles (p = 0.12), and smaller AVM nidus diameter (p = 0.17) correlated positively with high obliteration rates (> 90%). In the multivariate analysis, microcatheter tip detachment was the only independent variable associated with high obliteration rates (OR 9.5; p = 0.03). CONCLUSIONS The use of the Apollo detachable-tip microcatheter for embolization of AVMs and AVFs is associated with high rates of successful catheterization and obliteration and low rates of morbidity and mortality. The microcatheter was retrieved in all cases, even after prolonged injections in distal branch pedicles, often with significant reflux. This study represents the largest case series on the application of the Apollo microcatheter for neurointerventional procedures.
T he development of N-butyl cyanoacrylate (NBCA; Trufill NBCA liquid embolic system, DePuy Synthes) and ethylene vinyl alcohol (EVOH; Onyx liquid embolic system, Covidien/Medtronic) liquid embolysates has revolutionized the endovascular management of arteriovenous malformations (AVMs) and arteriovenous fistulas (AVFs). Trufill and Onyx were approved by the US FDA in September 2000 and July 2005, respectively, for preoperative embolization of brain AVMs. Disadvantages associated with the use of cyanoacrylates for the embolization of AVMs include their rapid polymerization, steep operator learning curve, unpredictable embolization pattern, and the frequent occurrence of microcatheter entrapment or the need for intraprocedural microcatheter exchange. The nonadhesive properties of EVOH have overcome some of the disadvantages encountered with the use of cyanoacrylates. Nonetheless, in 2012 the FDA issued a safety communication alert for the potential risks of catheter entrapment also associated with the use of Onyx. Since 2005, more than 100 cases of catheter breakage or entrapment have been reported to the FDA, including 9 deaths. 35 In at least 54 of those cases, the microcatheter could not be retrieved.
In 2006, the Sonic flow-directed, braided microcatheter (Balt Extrusion) became the first detachable-tip microcatheter to be approved for Onyx embolization of AVMs. 4, 20, 22, 33, 34, 36 The Sonic microcatheter, however, has not been approved by the FDA for the US market. In May 2014, the Apollo detachable-tip microcatheter (Covidien/ Medtronic; Fig. 1 ) became the first detachable-tip microcatheter to receive FDA approval for embolization of brain AVMs using the Onyx liquid embolic system in the US. This microcatheter has been successfully used off-label for the embolization of AVFs, vein of Galen malformations, and hypervascular tumors. 2, 12, 13, 15, 24, 31 A few authors have reported their initial experience with its concomitant use with NBCA. 2, 24 However, the neurointerventional literature has consisted mainly of small, single-institution case series or case reports. An ongoing postmarket safety study designed as a prospective registry (clinical trial no. NCT02378883, ClinicalTrials.gov) is currently in the enrollment phase at 24 centers in the US, but the study's preliminary results are currently unpublished.
In this study, we retrospectively reviewed the utility of the Apollo detachable-tip microcatheter for endovascular embolization of AVMs and AVFs. Special attention was focused on applications of the microcatheter, its safety profile, and technical implications for its use in neurointerventionalist practice. We also review the literature related to published case series on the use of the Sonic or Apollo microcatheter.
Methods
A retrospective review was conducted using 2 independent, prospectively collected endovascular patient databases from 2 high-volume, tertiary cerebrovascular referral centers (Barrow Neurological Institute and the University of Pittsburgh Medical Center). Institutional review board approval was obtained independently from both study sites.
The medical charts of all patients treated endovascularly for an intracranial AVM or AVF from July 2014 to October 2016 were analyzed. Operative reports and treatment angiographic studies were reviewed, and patients in whom at least one Apollo detachable microcatheter was used were identified (n = 61). Demographics and characteristics were collected for patients and lesions, including patient age and sex, clinical presentation, lesion location and size, Spetzler-Martin AVM grade, presence of perinidal or intranidal aneurysms, and adjuvant treatment (either resection or stereotactic radiosurgery). In addition, descriptive endovascular variables related to the use of the Apollo microcatheter were reviewed, such as number of catheterized pedicles and embolization sessions, type of liquid embolic agent used, endovascular angiographic obliteration, and microcatheter detachment tip status. Endovascular-and Apollo-related morbidity and mortality rates were calculated. Functional outcome at last followup was determined using the modified Rankin Scale. 7 The detachment status of the microcatheter tip after embolization was determined using 2 methods: review of the operative report and direct review of follow-up angiographic images. Cases in which the operative report clearly stated the detachment status of the microcatheter after retrieval or those in which a definite detached tip could be identified or excluded on the postembolization control angiogram were defined as positive detachment or negative detachment. Cases were defined as undetermined if the detachment status information was missing from the operative report or if the microcatheter tip could not be accurately identified on the postembolization images by 3 independent reviewers (B.C.F., A.P.S., and G.M.W.).
Continuous variables are reported as mean, median, and standard deviation, as applicable. Categorical and continuous variables were collected for all patients described above, independent of microcatheter tip detachment status. The correlations between detachment status of the Apollo tip and several dependent variables were analyzed using openly available statistical software (R, version 3.0; R Project for Statistical Computing Free Software Foundation, Inc.). The obliteration rate was categorized as ≤ 90% or > 90%. The diameter of the AVM and the number of embolization sessions were assessed in a continuous fashion; the number of pedicles was categorized as ≥ 1. The association between detachment and continuous dependent variables was performed using generalized linear models applying the glm function in R (version 3.0) with methods as implemented in the R Project for Statistical Computing. The association between detachment and the categorical percentage of obliteration was assessed using Fisher's exact test as implemented in the R Project for Statistical Computing. On univariate analysis, variables with values of p < 0.2 were selected for inclusion in the multivariate model. Multivariate analysis was completed with the generalized linear model applying the glm function. A p value < 0.05 was defined for statistical significance.
Finally, a Medline/PubMed literature search was conducted using the terms "detachable tip microcatheter," "Sonic microcatheter," and "Apollo microcatheter." Retrieved studies were then analyzed, and lesion type, number of embolized pedicles, microcatheter used, tip detachment status, and Apollo/Sonic-specific morbidity and mortality rates were recorded. On univariate analysis, microcatheter tip detachment (p = 0.12), single embolized pedicles (p = 0.12), and smaller nidus diameter (p = 0.17) were independent variables that appeared to be associated with the likelihood of high (> 90%) AVM obliteration rates (p < 0.20). The number of embolization sessions did not appear to correlate with angiographic obliteration. On multivariate analysis, the detachment of a microcatheter tip was the only independent variable with a positive association with high AVM obliteration rates (OR 9.5, 95% CI 1.5-98; p = 0.03).
Results

From
The Apollo microcatheter was successfully retrieved in all cases, and no instances of catheter entrapment were observed. No inadvertent tip detachment, microcatheter breakage, or perforation was observed. Endovascular-related morbidity occurred in 5 patients. In 3 patients with transient complications, there was 1 occurrence each of asymptomatic Onyx pulmonary embolism, proximal vertebral artery guide catheter dissection with an asymptomatic infarct, and transient diplopia after a cerebellar AVM embolization. In 2 patients with permanent complications, there was 1 occurrence each of brainstem infarction and arterial feeder microcatheter perforation with symptomatic intracerebral hemorrhage (using a Marathon microcatheter [Covidien/Medtronic]). Thus, the rate of transient endovascular-related morbidity was 3.8% (3/79) and the rate of permanent morbidity was 2.5% (2/79) per procedure, with an overall morbidity per procedure of 6.3% (5/79). No complication was directly associated with selection of the Apollo microcatheter. Three (4.9%) of 61 patients who were hospitalized died during their hospital stay. Two of these patients died of complications related to the initial hemorrhage at presentation. One patient died of an endovascular-related complication, for a per-procedure mortality rate of 1.3% (1/79). This patient was a 40-year-old man with a ruptured AVM in the right cerebellar hemisphere. During attempts to obtain distal microcatheter positioning into the right anterior inferior cerebellar artery for Onyx embolization of the AVM, he suffered a fatal intraoperative hemorrhage from a flow-related aneurysm.
Discussion
Detachable-tip microcatheters are intended to reduce the risk of catheter entrapment during the deployment of liquid embolysate. The technical principle of a detachabletip microcatheter for embolization of intracranial AVMs is not new; the first microcatheter with this feature (Sonic flow-directed, braided microcatheter) was released in Europe in 2006, and case reports of its successful application for Onyx 34 and NBCA 22 embolization were first reported in 2008. Several European centers have published their initial experiences with this device. 20, 22, 33, 34, 36 However, experience with this device outside Europe is limited, and the microcatheter has not received FDA approval as of the time of the writing of this paper.
Since the approval of the Apollo detachable-tip microcatheter by the FDA in 2014, its successful use has been reported in only a few small case series. 1, 2, 12, 13, 15, 24, 31 It has 2 radiopaque markers: one at the microcatheter distal tip According to the manufacturer, a thumb pressure of 0.16 ml/min is recommended as the injection rate (maximum 0.3 ml/min) for the Onyx liquid embolic system. Successful tip detachment should occur under atraumatic forces of approximately 33g. The force needed for microcatheter extraction is variable, depending on factors such as vessel tortuosity, amount of reflux, and proximal access support. Traction of 3-5 cm might be observed before microcatheter withdrawal. In some cases, it can be verified by increasing distances between the proximal and distal markers under direct fluoroscopic visualization. 12 Prolonged injection pauses (> 2 minutes) should be avoided to minimize the possibility of microcatheter occlusion.
The long-term risks associated with a retained catheter are not well known. It may become fixed to the arterial wall or it may be mobile, which can result in delayed thromboembolic complications. 24 Although the newer hydrophilic coated microcatheters have improved navigation and safety, the theoretical concern for retained microcatheters remains a limiting factor in embolization with either NBCA or Onyx. 2 The feared risk of microcatheter retention or target vessel rupture during microcatheter retrieval limits the amount of embolysate used with each embolization. Detachable-tip microcatheters have been developed to circumvent these limitations. They allow for more controlled and longer injections, and for better lesion penetration with minimized risk of microcatheter retention. Our recent systematic review of the endovascular literature reported a 3.4% per patient incidence of microcatheter retention after embolization of intracranial AVMs. 8 Despite the advantages of the Apollo microcatheter, neurointerventionalists should be cognizant of some important technical nuances associated with its use. The distal tip is very fragile, and it should be handled with care to avoid unintended premature detachment. The Apollo introducer sheath should always be used to prevent inadvertent microcatheter tip damage during introduction into the guide catheter or intermediate catheters. The integrity of the microcatheter tip should be verified before reinsertion of the guidewire and before each embolysate injection to prevent vascular damage or unintended delivery of embolysate through a fractured detachment zone. Review of the integrity of the tip can typically be achieved with contrast injection and angiographic visualization of contrast from the catheter tip while viewing the entire distal section of the catheter. Unlike standard dimethyl sulfoxide (DMSO)-compatible microcatheters, the Apollo catheter should not be repositioned after the start of Onyx injections; one should also not attempt to clear an "Onyxclogged" device by high-pressure infusion. 13 The current study represents the largest case series published to date on the safety and application of the Apollo detachable-tip microcatheter for the endovascular treatment of intracranial AVMs and AVFs (Table 3) . 1, 2, 4, 12, 13, 15, 20, 22, 31, 33, 34, 36 In this study, the successful catheterization rate was high (97.2%, 172/177), which underscores the adequate navigability of the microcatheter even in small, distal arterial branches that are difficult to navigate, despite its soft distal tip. There were no cases of unintended tip detachment of retained microcatheters in more than 170 catheterizations. Despite the fact that the majority of patients in this series underwent embolization as an adjunctive therapy to radiosurgery or microsurgery, 75% or more of the lesion volume was successfully embolized in nearly one-half of the patients (Fig. 2) . More importantly, the high obliteration rate was achieved with a single embolization session in 82% (50/61) of the patients, which indirectly emphasizes the more aggressive nature of embolization using detachable-tip microcatheters. On multivariate analysis, tip detachment showed a strong correlation with high AVM obliteration rates; patients in whom more than 90% of their AVMs were obliterated were 9.5 times more likely to present with at least one Apollo tip detachment. Often, the use of a detachable-tip microcatheter allowed for more aggressive and consistent embolization (Fig. 3) .
In some cases, the Apollo microcatheter was used in combination with a DMSO-compatible standard microcatheter that was positioned proximally on the same arterial pedicle, for an efficient, modified pressure cooker technique. 4 The incidence of endovascular-related morbidity was low (transient and permanent morbidity rates of 3.8% [3/79] and 2.5% [2/79], respectively) compared with our recently published institutional experience of endovascular treatment of cerebral AVMs in the pre-Apollo era (transient and permanent morbidity, 1.8% and 9.6%, respectively).
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Our complication rate also compares favorably with the rates in other institutional multimodality embolization series in adults and children, which range from 6.7% to 11%. 3, 16, 18 It is important to emphasize that none of the complications observed in the current study were directly related to use of the Apollo microcatheter or unintended premature tip detachment. One hemorrhagic complication occurred due to rupture of a flow-related aneurysm during distal catheterization using an Apollo microcatheter; however, the aneurysm rupture had no direct correlation with the Apollo microcatheter detachable-tip features.
AVM complexity in this series is similar to that reported in other contemporary embolization series, with a mean Spetzler-Martin grade of 2.4. 3, 6 In this series, a greater propensity for multimodality treatment was evident, with nearly 80% of patients undergoing microsurgery or radiosurgery, compared with 9% in the 2014 report by Baharvahdat et al. 3 Several studies that have recently reported high angiographic cure rates using Onyx embolization to treat intracranial AVMs have primarily been based on the use of detachable-tip microcatheters. 1, 6, 20, 29, 36 Comparatively, the results from the current study also appear to be congruent with reports from some of the largest published studies on Onyx embolization of brain AVMs (Table 4) . 10, 11, 14, 17, 19, 21, 23, [25] [26] [27] [28] 30, 32, 35, [37] [38] [39] [40] Some financial aspects should be considered by the neurointerventionalist when deciding between the use of a standard Onyx-compatible microcatheter and the Apollo detachable-tip microcatheter. Despite the theoretical advantage of the Apollo in reducing the probability of a retained catheter and allowing for more aggressive embolization through a single pedicle access, the price difference between these microcatheters can be substantial. Commercial data obtained from the manufacturer show that the cost of the Apollo microcatheter could be almost twice the price of the Marathon flow-guided microcatheter ($2145 vs $1130; personal communication). In specific situations, this cost difference can be offset by potential decreases in the number of microcatheters exchanged and in the number of arterial pedicles catheterized, both of which are allowed by a higher tolerance to Onyx associated with a detachable-tip mechanism.
The possibility of microcatheter retention raises potential complications that are different from those of other catheter designs. Few reports have been published on the safety of this catheter. The long-term consequences of tip retention are still poorly understood. Tip retention would be especially problematic in cases in which embolization was used as monotherapy or associated with stereotactic radiosurgery and surgical retrieval of a catheter tip would not be possible. Potential complications of tip retention may be elucidated by an ongoing postmarket safety study to evaluate the safety of the Apollo delivery microcatheter for brain AVM embolization procedures (clinical trial no. NCT02378883). This postmarket registry, with an estimated enrollment of 161 patients, has not yet released preliminary data. A similar clinical trial is evaluating the safety of the Apollo microcatheter in pediatric patients (clinical trial no. NCT02085278).
The current study has a number of limitations. The retrospective nature of the data collection introduces natural selection bias inherent to this type of study. The Apollo catheter was not necessarily used in isolation; given the retrospective nature of this study, it is not possible to determine which adjunctive catheters were used due to perceived or actual navigation limitations of the Apollo itself. In 7% of the Apollo microcatheterizations, the tip detachment status could not be determined by operative report or angiographic imaging review. The heterogeneity of the studied groups is accentuated by the multiinstitutional nature of the data collection. Finally, no matched control groups with similar lesions treated with standard DMSOcompatible microcatheters are available for comparison, and the pre-Apollo data presented in this article derive exclusively from a systematic review of the literature.
Conclusions
Use of the Apollo detachable-tip microcatheter for embolization of AVMs and AVFs is associated with high rates of successful catheterization and obliteration and low rates of morbidity and mortality. This microcatheter system allows the neurointerventionalist the option of a more aggressive embolization, with prolonged injection time and higher tolerance for Onyx or NBCA reflux. In the current study, the Apollo microcatheter was retrieved in all cases, even after prolonged injections in distal branch pedicles, often with significant reflux. In multivariate analysis, tip detachment was significantly associated with higher AVM or AVF obliteration rates. The current study represents the largest case series on the use of the Apollo microcatheter for neurointerventional procedures. Further studies are needed to evaluate the long-term safety of retained detachable tips in patients who do not undergo adjuvant resection.
